30-day readmission rate higher in HF patients with amyloidosis than without
Patients admitted with HF with amyloidosis had a higher 30-day, all-cause readmission rate and longer hospital stay vs. HF patients without amyloidosis, study data presented at the American Heart Association Scientific Sessions show.
Iriagbonse Asemota, MD, of John H. Stroger Hospital of Cook County in Chicago, and colleagues compared the nonelective 30-day readmission rates among HF patients hospitalized with and without an amyloidosis diagnosis.
The investigators used the 2018 nationwide readmissions database to identify patients with a principal discharge diagnosis of HF and stratified all-cause, 30-day readmissions into two groups: those with coexisting amyloidosis and those without. They compared baseline characteristics between readmissions (using chi-square tests) as well as the mean length of hospital stay and total hospital charge (using regression analysis) for both groups.
The results showed that HF patients with coexisting amyloidosis had a greater 30-day, all-cause readmission rate (22% vs. 16.5%; P = .03) and stayed longer in the hospital, with 4.25 days-increase in the unadjusted mean length of stay, (5.68 vs. 9.94 days; P = .026) compared with HF patients without amyloidosis. In addition, HF patients in the amyloidosis group were older (68.4 vs. 64.7 years), were at higher risk of inpatient mortality (adjusted OR = 2.69) and had a $30,525 higher total hospital charge ($84,549 vs. $54,024; P= .11) compared with HF patients without amyloidosis.
“These results signal that early risk stratification and intensive treatment may help reduce unplanned readmission rates among heart failure patients with amyloidosis,” Asemota said during the presentation.
Collapse
Asemota I, et al. P1895. Presented at: American Heart Association Scientific Sessions; Nov. 13-15, 2021 (virtual meeting).